ELSEVIER

Diabetes Research and Clinical Practice 49 (2000) 201–203

DIABETES RESEARCH AND CLINICAL PRACTICE

www.elsevier.com/locate/diabres

Author index of volume 49

Abe, T., see Awata, T. **49**, 61
Abe, T., see Hayakawa, T. **49**, 195
Acheampong, J.W., see Amoah, A.G.B. **49**, 149
Adachi, H., F.C. Goetz, D.R. Jacobs, Jr, M. Tsuruta, Y. Hirai, Y. Fujiura, T. Imaizumi, The role of obesity in the association of cardiovascular risk factors and glucose intolerance in small Japanese and North American communities **49**, 41
Adamu, F.C., see Amoah, A.G.B. **49**, 149
Agyenim-Boateng, K., see Amoah, A.G.B. **49**, 149
Aida, K., see Tawata, M. **49**, 17
Aizawa, T., see Yamada, T. **49**, 23
Ambady, R., see Viswanathan, V. **49**, 143
Amegashie, R.A., see Amoah, A.G.B. **49**, 149
Amemiya, S., see Aono, S. **49**, 135
Amoah, A.G.B., S.K. Owusu, J.W. Acheampong, K. Agyenim-Boateng, H.R. Asare, A.A. Owusu, M.F. Mensah-Poku, F.C. Adamu, R.A. Amegashie, J.T. Saunders, W.L. Fang, J.G. Pastors, C. Sanborn, E.J. Barrett, M.K.A. Woode, A national diabetes care and education programme: the Ghana model **49**, 149
Ando, H., see Hayakawa, T. **49**, 195
Aono, S., N. Matsuura, S. Amemiya, Y. Igarashi, Y. Uchigata, T. Urakami, K. Kida, N. Sasaki, Y. Miki, S. Miyamoto, Marriage rate and number of children among young adults with insulin-dependent diabetes mellitus in Japan **49**, 135
Armstrong, D.G., see Wunderlich, R.P. **49**, 87
Asare, H.R., see Amoah, A.G.B. **49**, 149
Awata, T., K. Inoue, I. Inoue, T. Abe, H. Takino, Y. Kanazawa, S. Katayama, Lack of association of the Ala45Thr variant in the BETA2/NEUROD1 with type 1 diabetes in Japanese **49**, 61

Barrett, E.J., see Amoah, A.G.B. **49**, 149

Castells, I., I. Salinas, F. Rius, M. Fraile, L. Rubio, D. Pereferrer, R. Romero, A. Sanmartí, Inducible myocardial ischaemia in asymptomatic Type 2 diabetic patients **49**, 127
Chairopoulos, K., see Migdalis, I.N. **49**, 113
Chamukuttan, S., see Viswanathan, V. **49**, 143
Chew, S.K., see Tai, E.S. **49**, 159
Choi, C.S., C.-H. Kim, W.J. Lee, J.Y. Park, S.K. Hong, M.G. Lee, S.W. Park, K.-U. Lee, Association between birth weight and insulin sensitivity in healthy young men in Korea: role of visceral adiposity **49**, 53
Clifford, K.S., M.J. MacDonald, Survey of mRNAs encoding zinc transporters and other metal complexing proteins in pancreatic islets of rats from birth to adulthood: similar patterns in the Sprague–Dawley and Wistar BB strains **49**, 77
Cockram, C., Editorial Comment **49**, 75

Diosdado, M.A., see Rattarasarn, C. **49**, 107

Fang, W.L., see Amoah, A.G.B. **49**, 149
Fraile, M., see Castells, I. **49**, 127
Fujii, S., see Yamamoto, T. **49**, 65
Fujiura, Y., see Adachi, H. **49**, 41

Goetz, F.C., see Adachi, H. **49**, 41
Goswami, R., A. Jaleel, N.P. Kochupillai, Insulin antibody response to bovine insulin therapy: functional significance among insulin requiring young diabetics in India **49**, 7

Half-Onn, E., see Rachmani, R. **49**, 187
Harada, H., see Ito, C. **49**, 181
Hasegawa, T., see Yamamoto, T. **49**, 65
Hashizume, K., see Yamada, T. **49**, 23
Hayakawa, T., Y. Nagai, H. Ando, H. Yamashita, T. Takamura, T. Abe, G. Nomura, K.-i. Kobayashi, S20G mutation of the amylin gene in Japanese patients with type 2 diabetes **49**, 195
Hayashi, K., see Uto, H. **49**, 101
Hirai, Y., see Adachi, H. **49**, 41
Hirono, S., see Uto, H. **49**, 101
Hong, S.K., see Choi, C.S. **49**, 53
Hori, T., see Uto, H. **49**, 101
Hosoi, M., see Yamamoto, T. **49**, 65

PII: S0168-8227(00)00185-6

Ido, A., see Uto, H. **49**, 101
Igarashi, Y., see Aono, S. **49**, 135
Ikeda, M., see Tawata, M. **49**, 17
Imaizumi, T., see Adachi, H. **49**, 41
Inoue, I., see Awata, T. **49**, 61
Inoue, K., see Awata, T. **49**, 61
Inoue, N., see Ito, C. **49**, 181
Irie, S., see Kaku, K. **49**, 119
Ishida, S., see Ito, C. **49**, 181
Ishii, T., see Yamamoto, T. **49**, 65
Ismail, R.B., see Wan Mohamad, W.B. **49**, 93
Ito, C., R. Maeda, S. Ishida, H. Harada, N. Inoue, H. Sasaki, Importance of OGTT for diagnosing diabetes mellitus based on prevalence and incidence of retinopathy **49**, 181

Jacobs, D.R., Jr, see Adachi, H. **49**, 41
Jaleel, A., see Goswami, R. **49**, 7
Jaruratanasirikul, S., see Rattarasarn, C. **49**, 107

Kaku, K., M. Matsuda, A. Urae, S. Irie, Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers **49**, 119
Kammerer, L., see Tóth, L. **49**, 1
Kanazawa, Y., see Awata, T. **49**, 61
Karmaniolas, K., see Migdalis, I.N. **49**, 113
Katayama, S., see Awata, T. **49**, 61
Kida, K., see Aono, S. **49**, 135
Kim, C.-H., see Choi, C.S. **49**, 53
Kobayashi, K.-i., see Hayakawa, T. **49**, 195
Kochupillai, N.P., see Goswami, R. **49**, 7
Kodama, Y., see Tawata, M. **49**, 17
Komatsu, M., see Yamada, T. **49**, 23
Kuniyil, S., see Viswanathan, V. **49**, 143

Lavery, L.A., see Wunderlich, R.P. **49**, 87
Lee, K.-U., see Choi, C.S. **49**, 53
Leelawattana, R., see Rattarasarn, C. **49**, 107
Lee, M.G., see Choi, C.S. **49**, 53
Lee, W.J., see Choi, C.S. **49**, 53
Lengyel, Z., see Tóth, L. **49**, 1
Leontiades, E., see Migdalis, I.N. **49**, 113
Levi, Z., see Rachmani, R. **49**, 187
Lidar, M., see Rachmani, R. **49**, 187
Lim, S.C., see Tai, E.S. **49**, 159
Liptai, M., see Tóth, L. **49**, 1

MacDonald, M.J., see Clifford, K.S. **49**, 77
Maeda, R., see Ito, C. **49**, 181
Mafauzy, M., see Wan Mohamad, W.B. **49**, 93
Matsuda, M., see Kaku, K. **49**, 119
Matsuoka, H., see Uto, H. **49**, 101
Matsuura, N., see Aono, S. **49**, 135
Mensah-Poku, M.F., see Amoah, A.G.B. **49**, 149
Metcalf, P.A., R.K.R. Scragg, Comparison of WHO and ADA criteria for diagnosis of glucose status in adults **49**, 169
Migdalis, I.N., K. Xenos, K. Chairopoulos, N. Varvarigos, E. Leontiades, K. Karmaniolas, Ca^{2+}-Mg^{2+}-ATPase activity and ionized calcium in Type 2 diabetic patients with neuropathy **49**, 113
Miki, Y., see Aono, S. **49**, 135
Mitsuhashi, T., see Yamada, T. **49**, 23
Miyamoto, M., see Yamamoto, T. **49**, 65
Miyamoto, S., see Aono, S. **49**, 135
Miyata, Y., see Uto, H. **49**, 101
Mori, T., see Yamamoto, T. **49**, 65
Müller, U.A., see Schiel, R. **49**, 33
Murata, M., see Uto, H. **49**, 101

Nagai, Y., see Hayakawa, T. **49**, 195
Németh, C., see Tóth, L. **49**, 1
Nishimori, T., see Yamada, T. **49**, 23
Nomura, G., see Hayakawa, T. **49**, 195

Okamoto, T., see Uto, H. **49**, 101
Onaya, T., see Tawata, M. **49**, 17
Ortego, J., see Rattarasarn, C. **49**, 107
Owusu, A.A., see Amoah, A.G.B. **49**, 149
Owusu, S.K., see Amoah, A.G.B. **49**, 149

Park, J.Y., see Choi, C.S. **49**, 53
Park, S.W., see Choi, C.S. **49**, 53
Pastors, J.G., see Amoah, A.G.B. **49**, 149
Patarakijvanich, N., see Rattarasarn, C. **49**, 107
Pereferrer, D., see Castells, I. **49**, 127
Peters, E.J.G., see Wunderlich, R.P. **49**, 87

Rachmani, R., Z. Levi, M. Lidar, I. Slavachevski, E. Half-Onn, M. Ravid, Considerations about the threshold value of microalbuminuria in patients with diabetes mellitus: lessons from an 8-year follow-up study of 599 patients **49**, 187
Rattarasarn, C., M.A. Diosdado, J. Ortego, R. Leelawattana, S. Soonthornpun, W. Setasuban, S. Jaruratanasirikul, N. Patarakijvanich, Thyroid autoantibodies in Thai type 1 diabetic patients: clinical significance and their relationship with glutamic acid decarboxylase antibodies **49**, 107
Ravid, M., see Rachmani, R. **49**, 187
Rius, F., see Castells, I. **49**, 127
Romero, R., see Castells, I. **49**, 127
Rubio, L., see Castells, I. **49**, 127

Sagai, H., see Yamada, T. **49**, 23
Salinas, I., see Castells, I. **49**, 127
Sanborn, C., see Amoah, A.G.B. **49**, 149
Sanmartí, A., see Castells, I. **49**, 127
Sasaki, H., see Ito, C. **49**, 181
Sasaki, N., see Aono, S. **49**, 135
Sato, A., see Yamada, T. **49**, 23
Sato, T., see Yamamoto, T. **49**, 65
Saunders, J.T., see Amoah, A.G.B. **49**, 149
Schiel, R., U.A. Müller, GAD autoantibodies in a selection-free population of insulin-treated diabetic patients: indicator of a high prevalence of LADA? **49**, 33

Scragg, R.K.R., see Metcalf, P.A. **49**, 169
Setasuban, W., see Rattarasarn, C. **49**, 107
Slavachevski, I., see Rachmani, R. **49**, 187
Soonthornpun, S., see Rattarasarn, C. **49**, 107

Tai, E.S., S.C. Lim, S.K. Chew, B.Y. Tan, C.E. Tan, Homeostasis model assessment in a population with mixed ethnicity: the 1992 Singapore National Health Survey **49**, 159
Takamura, T., see Hayakawa, T. **49**, 195
Takino, H., see Awata, T. **49**, 61
Tanaka, S., see Yamamoto, T. **49**, 65
Tan, B.Y., see Tai, E.S. **49**, 159
Tan, C.E., see Tai, E.S. **49**, 159
Tawata, M., M. Ikeda, Y. Kodama, K. Aida, T. Onaya, A type 2 diabetic patient with liver dysfunction due to human insulin **49**, 17
Terao, A., see Yamada, T. **49**, 23
Tóth, L., P. Vörös, Z. Lengyel, M. Liptai, C. Németh, L. Kammerer, Diurnal blood pressure variations in incipient and end stage diabetic renal disease **49**, 1
Tsubouchi, H., see Uto, H. **49**, 101
Tsuruta, M., see Adachi, H. **49**, 41
Tun Fizi, A., see Wan Mohamad, W.B. **49**, 93

Uchigata, Y., see Aono, S. **49**, 135
Urae, A., see Kaku, K. **49**, 119
Urakami, T., see Aono, S. **49**, 135
Uto, H., H. Matsuoka, M. Murata, T. Okamoto, Y. Miyata, T. Hori, A. Ido, S. Hirono, K. Hayashi, H. Tsubouchi, A case of chronic hepatitis C developing insulin-dependent diabetes mellitus associated with various autoantibodies during interferon therapy **49**, 101

Varvarigos, N., see Migdalis, I.N. **49**, 113
Viswanathan, V., S. Chamukuttan, S. Kuniyil, R. Ambady, Evaluation of a simple, random urine test for prospective analysis of proteinuria in Type 2 diabetes: a six year follow-up study **49**, 143
Vörös, P., see Tóth, L. **49**, 1

Wan Mohamad, W.B., A. Tun Fizi, R.B. Ismail, M. Mafauzy, Efficacy and safety of single versus multiple daily doses of glibenclamide in type 2 diabetes mellitus **49**, 93
Woode, M.K.A., see Amoah, A.G.B. **49**, 149
Wunderlich, R.P., E.J.G. Peters, D.G. Armstrong, L.A. Lavery, Reliability of digital videometry and acetate tracing in measuring the surface area of cutaneous wounds **49**, 87

Xenos, K., see Migdalis, I.N. **49**, 113

Yamada, T., A. Sato, T. Nishimori, T. Mitsuhashi, A. Terao, H. Sagai, M. Komatsu, T. Aizawa, K. Hashizume, Importance of hypercoagulability over hyperglycemia for vascular complication in type 2 diabetes **49**, 23
Yamakita, T., see Yamamoto, T. **49**, 65
Yamamoto, T., T. Sato, T. Mori, T. Yamakita, T. Hasegawa, M. Miyamoto, M. Hosoi, T. Ishii, K. Yoshioka, S. Tanaka, S. Fujii, Clinical efficacy of insulin-like growth factor-1 in a patient with autoantibodies to insulin receptors: a case report **49**, 65
Yamashita, H., see Hayakawa, T. **49**, 195
Yoshioka, K., see Yamamoto, T. **49**, 65
Yung, B., Letter to the Editor **49**, 199

ELSEVIER

Diabetes Research and Clinical Practice 49 (2000) 205–208

DIABETES RESEARCH AND CLINICAL PRACTICE

www.elsevier.com/locate/diabres

Subject index of volume 49

Abdominal obesity; Insulin resistance; Insulin secretion; Type 2 diabetes; Birth weight **49**, 53

Albuminuria; Asymptomatic myocardial ischaemia; Thallium-SPECT; Type 2 diabetes mellitus **49**, 127

Amylin gene; Mutation; Type 2 diabetes **49**, 195

Anti-GAD; Diabetes mellitus; Type 1; Type 2; Diabetes long-term complications; Latent autoimmune diabetes mellitus in adults (LADA) **49**, 33

Anti-insulin receptor antibodies; Type B insulin-resistance syndrome; Insulin-like growth factor-1; Insulin-like growth factor-1 allergy **49**, 65

Asymptomatic myocardial ischaemia; Albuminuria; Thallium-SPECT; Type 2 diabetes mellitus **49**, 127

Autoantibody; Chronic hepatitis C; Insulin-dependent diabetes mellitus; Interferon **49**, 101

Beta cell function; Insulin resistance; Coronary artery disease; Homeostasis model assessment **49**, 159

BETA2/NEUROD1; Type 1 diabetes; Japanese **49**, 61

Birth weight; Insulin resistance; Insulin secretion; Abdominal obesity; Type 2 diabetes **49**, 53

Blood glucose; Insulin; Free fatty acids; Obesity **49**, 41

Blood pressure monitoring; Diabetic nephropathy; Micro-albuminuria; Peritoneal dialysis; Haemodialysis **49**, 1

Bovine insulin; Insulin antibody; Total insulin binding power; Daily insulin dose requirement; Young diabetics; Malnutrition modulated form of diabetes; India **49**, 7

Calreticulin; Metal-complexing proteins; mRNAs **49**, 77

Ca^{2+}-Mg^{2+}-ATPase activity; Peripheral neuropathy; Type 2 diabetes **49**, 113

Care; Diabetes; Programme; Development; Implementation; Education; Hospitals; National; Ghana; Guidelines **49**, 149

Cholestasis; Liver dysfunction; Hepatocellular damages; Human insulin; Diabetes mellitus **49**, 17

Chronic hepatitis C; Autoantibody; Insulin-dependent diabetes mellitus; Interferon **49**, 101

Coagulation; Fibrinolysis; Type 2 diabetes; Diabetic complications **49**, 23

Coronary artery disease; Insulin resistance; Beta cell function; Homeostasis model assessment **49**, 159

Daily insulin dose requirement; Bovine insulin; Insulin antibody; Total insulin binding power; Young diabetics; Malnutrition modulated form of diabetes; India **49**, 7

Development; Diabetes; Care; Programme; Implementation; Education; Hospitals; National; Ghana; Guidelines **49**, 149

PII: S0168-8227(00)00186-8

Diabetes; Care; Programme; Development; Implementation; Education; Hospitals; National; Ghana; Guidelines **49**, 149

Diabetes; Diagnostic criteria; Impaired glucose tolerance; Fasting glucose **49**, 169

Diabetes long-term complications; Anti-GAD; Diabetes mellitus; Type 1; Type 2; Latent autoimmune diabetes mellitus in adults (LADA) **49**, 33

Diabetes mellitus; Anti-GAD; Type 1; Type 2; Diabetes long-term complications; Latent autoimmune diabetes mellitus in adults (LADA) **49**, 33

Diabetes mellitus; Liver dysfunction; Cholestasis; Hepatocellular damages; Human insulin **49**, 17

Diabetes mellitus type 2; Microalbuminuria; Screening **49**, 187

Diabetes; Wound; Ulcer; Neuropathy; Measurement; Reliability **49**, 87

Diabetic complications; Coagulation; Fibrinolysis; Type 2 diabetes **49**, 23

Diabetic nephropathy; Blood pressure monitoring; Micro-albuminuria; Peritoneal dialysis; Haemodialysis **49**, 1

Diagnostic criteria; Diabetes; Impaired glucose tolerance; Fasting glucose **49**, 169

Education; Diabetes; Care; Programme; Development; Implementation; Hospitals; National; Ghana; Guidelines **49**, 149

Epidemiology; IDDM; Marriage rate; Number of children; Questionnaire survey **49**, 135

Estimated protein estimation; Kidney function; Nephropathy; Proteinuria; Protein/creatinine ratio **49**, 143

Fasting glucose; Diabetes; Diagnostic criteria; Impaired glucose tolerance **49**, 169

Fibrinolysis; Coagulation; Type 2 diabetes; Diabetic complications **49**, 23

Free fatty acids; Blood glucose; Insulin; Obesity **49**, 41

Ghana; Diabetes; Care; Programme; Development; Implementation; Education; Hospitals; National; Guidelines **49**, 149

Glibendamide; Multiple daily doses; Single daily dose **49**, 93

Glutamic acid decarboxylase antibody; Thyroid antibody; Thyroid dysfunction; Type 1 diabetes **49**, 107

Guidelines; Diabetes; Care; Programme; Development; Implementation; Education; Hospitals; National; Ghana **49**, 149

Haemodialysis; Diabetic nephropathy; Blood pressure monitoring; Micro-albuminuria; Peritoneal dialysis **49**, 1

Hepatocellular damages; Liver dysfunction; Cholestasis; Human insulin; Diabetes mellitus **49**, 17

Homeostasis model assessment; Insulin resistance; Beta cell function; Coronary artery disease **49**, 159

Hospitals; Diabetes; Care; Programme; Development; Implementation; Education; National; Ghana; Guidelines **49**, 149

Human insulin; Liver dysfunction; Cholestasis; Hepatocellular damages; Diabetes mellitus **49**, 17

IDDM; Marriage rate; Number of children; Epidemiology; Questionnaire survey **49**, 135

IFG; OGTT evaluation criteria; OGTT 2-h PG; Prevalence of retinopathy; Incidence of retinopathy **49**, 181

Impaired glucose tolerance; Diabetes; Diagnostic criteria; Fasting glucose **49**, 169

Implementation; Diabetes; Care; Programme; Development; Education; Hospitals; National; Ghana; Guidelines **49**, 149

Incidence of retinopathy; OGTT evaluation criteria; OGTT 2-h PG; Prevalence of retinopathy; IFG **49**, 181

India; Bovine insulin; Insulin antibody; Total insulin binding power; Daily insulin dose requirement; Young diabetics; Malnutrition modulated form of diabetes **49**, 7

Insulin analog; Insulin aspart; Pharmacokinetics; Pharmacodynamics; Japanese **49**, 119

Insulin antibody; Bovine insulin; Total insulin binding power; Daily insulin dose requirement; Young diabetics; Malnutrition modulated form of diabetes; India **49**, 7

Insulin aspart; Insulin analog; Pharmacokinetics; Pharmacodynamics; Japanese **49**, 119

Insulin; Blood glucose; Free fatty acids; Obesity **49**, 41

Insulin-dependent diabetes mellitus; Autoantibody; Chronic hepatitis C; Interferon **49**, 101

Insulin-like growth factor-1 allergy; Type B insulin-resistance syndrome; Insulin-like growth factor-1; Anti-insulin receptor antibodies **49**, 65

Insulin-like growth factor-1; Type B insulin-resistance syndrome; Anti-insulin receptor antibodies; Insulin-like growth factor-1 allergy **49**, 65

Insulin resistance; Beta cell function; Coronary artery disease; Homeostasis model assessment **49**, 159

Insulin resistance; Insulin secretion; Abdominal obesity; Type 2 diabetes; Birth weight **49**, 53

Insulin secretion; Insulin resistance; Abdominal obesity; Type 2 diabetes; Birth weight **49**, 53

Interferon; Autoantibody; Chronic hepatitis C; Insulin-dependent diabetes mellitus **49**, 101

Japanese; BETA2/NEUROD1; Type 1 diabetes **49**, 61

Japanese; Insulin analog; Insulin aspart; Pharmacokinetics; Pharmacodynamics **49**, 119

Kidney function; Estimated protein estimation; Nephropathy; Proteinuria; Protein/creatinine ratio **49**, 143

Latent autoimmune diabetes mellitus in adults (LADA); Anti-GAD; Diabetes mellitus; Type 1; Type 2; Diabetes long-term complications **49**, 33

Liver dysfunction; Cholestasis; Hepatocellular damages; Human insulin; Diabetes mellitus **49**, 17

Malnutrition modulated form of diabetes; Bovine insulin; Insulin antibody; Total insulin binding power; Daily insulin dose requirement; Young diabetics; India **49**, 7

Marriage rate; IDDM; Number of children; Epidemiology; Questionnaire survey **49**, 135

Measurement; Wound; Ulcer; Diabetes; Neuropathy; Reliability **49**, 87

Metal-complexing proteins; Calreticulin; mRNAs **49**, 77

Microalbuminuria; Diabetes mellitus type 2; Screening **49**, 187

Micro-albuminuria; Diabetic nephropathy; Blood pressure monitoring; Peritoneal dialysis; Haemodialysis **49**, 1

mRNAs; Metal-complexing proteins; Calreticulin **49**, 77

Multiple daily doses; Glibendamide; Single daily dose **49**, 93

Mutation; Amylin gene; Type 2 diabetes **49**, 195

National; Diabetes; Care; Programme; Development; Implementation; Education; Hospitals; Ghana; Guidelines **49**, 149

Nephropathy; Estimated protein estimation; Kidney function; Proteinuria; Protein/creatinine ratio **49**, 143

Neuropathy; Wound; Ulcer; Diabetes; Measurement; Reliability **49**, 87

Number of children; IDDM; Marriage rate; Epidemiology; Questionnaire survey **49**, 135

Obesity; Blood glucose; Insulin; Free fatty acids **49**, 41

OGTT evaluation criteria; OGTT 2-h PG; Prevalence of retinopathy; Incidence of retinopathy; IFG **49**, 181

OGTT 2-h PG; OGTT evaluation criteria; Prevalence of retinopathy; Incidence of retinopathy; IFG **49**, 181

Peripheral neuropathy; Ca^{2+}-Mg^{2+}-ATPase activity; Type 2 diabetes **49**, 113

Peritoneal dialysis; Diabetic nephropathy; Blood pressure monitoring; Micro-albuminuria; Haemodialysis **49**, 1

Pharmacodynamics; Insulin analog; Insulin aspart; Pharmacokinetics; Japanese **49**, 119

Pharmacokinetics; Insulin analog; Insulin aspart; Pharmacodynamics; Japanese **49**, 119

Prevalence of retinopathy; OGTT evaluation criteria; OGTT 2-h PG; Incidence of retinopathy; IFG **49**, 181

Programme; Diabetes; Care; Development; Implementation; Education; Hospitals; National; Ghana; Guidelines **49**, 149

Protein/creatinine ratio; Estimated protein estimation; Kidney function; Nephropathy; Proteinuria **49**, 143

Proteinuria; Estimated protein estimation; Kidney function; Nephropathy; Protein/creatinine ratio **49**, 143

Questionnaire survey; IDDM; Marriage rate; Number of children; Epidemiology **49**, 135

Reliability; Wound; Ulcer; Diabetes; Neuropathy; Measurement **49**, 87

Screening; Microalbuminuria; Diabetes mellitus type 2 **49**, 187

Single daily dose; Glibendamide; Multiple daily doses **49**, 93

Thallium-SPECT; Albuminuria; Asymptomatic myocardial ischaemia; Type 2 diabetes mellitus **49**, 127

Thyroid antibody; Thyroid dysfunction; Glutamic acid decarboxylase antibody; Type 1 diabetes **49**, 107

Thyroid dysfunction; Thyroid antibody; Glutamic acid decarboxylase antibody; Type 1 diabetes **49**, 107

Total insulin binding power; Bovine insulin; Insulin antibody; Daily insulin dose requirement; Young diabetics; Malnutrition modulated form of diabetes; India **49**, 7

Type 2; Anti-GAD; Diabetes mellitus; Type 1; Diabetes long-term complications; Latent autoimmune diabetes mellitus in adults (LADA) **49**, 33

Type 1; Anti-GAD; Diabetes mellitus; Type 2; Diabetes long-term complications; Latent autoimmune diabetes mellitus in adults (LADA) **49**, 33

Type B insulin-resistance syndrome; Insulin-like growth factor-1; Anti-insulin receptor antibodies; Insulin-like growth factor-1 allergy **49**, 65

Type 2 diabetes; Amylin gene; Mutation **49**, 195

Type 1 diabetes; BETA2/NEUROD1; Japanese **49**, 61

Type 2 diabetes; Ca^{2+}-Mg^{2+}-ATPase activity; Peripheral neuropathy **49**, 113

Type 2 diabetes; Coagulation; Fibrinolysis; Diabetic complications **49**, 23

Type 2 diabetes; Insulin resistance; Insulin secretion; Abdominal obesity; Birth weight **49**, 53

Type 2 diabetes mellitus; Albuminuria; Asymptomatic myocardial ischaemia; Thallium-SPECT **49**, 127

Type 1 diabetes; Thyroid antibody; Thyroid dysfunction; Glutamic acid decarboxylase antibody **49**, 107

Ulcer; Wound; Diabetes; Neuropathy; Measurement; Reliability **49**, 87

Wound; Ulcer; Diabetes; Neuropathy; Measurement; Reliability **49**, 87

Young diabetics; Bovine insulin; Insulin antibody; Total insulin binding power; Daily insulin dose requirement; Malnutrition modulated form of diabetes; India **49**, 7